课题基金 / 基金详情

项目摘要

项目成果

JEFFREY B KAPLAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Project Summary/Abstract was modified to reflect the changes described above: A major risk associated with implanted medical devices is their high rate of infection. Bacteria that colonize medical devices form matrix-encased biofilms that resist antimicrobial therapy and are often difficult or impossible to eradicate. The extracellular matrix of Staphylococcus aureus and Staphylococcus epidermidis, the most common device-associated pathogens, contains a sticky polysaccharide named PNAG (poly-N-acetylglucosamine) that mediates surface attachment, intercellular adhesion, biocide resistance and immune evasion. Our laboratory discovered an enzyme (dispersin B) that degrades PNAG. Preliminary studies indicate that dispersin B inhibits staphylococcal biofilm formation, detaches pre-formed staphylococcal biofilms, and sensitizes staphylococcal biofilm cells to antimicrobial killing in vitro. Our hypothesis is that dispersin B will be a clinically useful anti-biofilm agent for the treatment and prevention of staphylococcal biofilm infections in vivo. The goal of the present proposal is to demonstrate that dispersin B acts synergistically with antibiotics to detach and kill S. aureus and S. epidermidis biofilms in vitro. Dispersin B will be tested both in solution in a simulated daily antibiotic catheter lock assay, and loaded onto polyurethane disks, either alone or in combination with antibiotics, in a model for antiinfective device coatings. The antibiotics that we plan to test include tigecycline and vancomycin. The results of the proposed studies will extend our knowledge about the mechanism of PNAGmediated biofilm resistance to specific antibiotics, and will demonstrate the feasibility of using dispersin B as anti-biofilm agent in vivo. Since dispersin B does not kill bacteria or inhibit their growth, dispersin B-based strategies may be less prone to the evolution of resistance than strategies utilizing conventional antibiotics.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Characterization of TEM-1 β-Lactamase-Producing Kingella kingae Clinical Isolates.
TEM-1 β-内酰胺酶生产 Kingella kingae 临床分离株的表征。
DOI: 10.1128/aac.00318-13
发表时间: 2013
期刊: Antimicrobial agents and chemotherapy
影响因子: 4.9
作者: [Banerjee,Anushree, Kaplan,JeffreyB, Soherwardy,Amenah, Nudell,Yoav, Mackenzie,GraceA, Johnson,Shannon, Balashova,NataliyaV]
通讯作者: Balashova,NataliyaV
DOI: 10.1038/ja.2011.113
发表时间: 2012-02
期刊: The Journal of antibiotics
影响因子: --
作者: []
通讯作者:
DOI: 10.1111/j.1462-2920.2012.02810.x
发表时间: 2013-02
期刊: Environmental microbiology
影响因子: 5.1
作者: [Rendueles O, Kaplan JB, Ghigo JM]
通讯作者: Ghigo JM
DOI: 10.1016/j.resmic.2011.03.008
发表时间: 2011-06
期刊: RESEARCH IN MICROBIOLOGY
影响因子: 2.6
作者: [Kaplan, Jeffrey B., Jabbouri, Said, Sadovskaya, Irina]
通讯作者: Sadovskaya, Irina
Biofilm matrix-degrading enzymes for the treatment and prevention of S. aureus-as
Biofilm matrix-degrading enzymes for the treatment and prevention of S. aureus-as
  • 批准号:
    8658802
  • 项目类别:
  • 资助金额:
    $17.68万
  • 财政年份:
    2012
  • 负责人:
    JEFFREY B KAPLAN
  • 依托单位:
Biofilm matrix-degrading enzymes for the treatment and prevention of S. aureus-as
  • 批准号:
    8450727
  • 项目类别:
  • 资助金额:
    $15.03万
  • 财政年份:
    2012
  • 负责人:
    JEFFREY B KAPLAN
  • 依托单位:
Biofilm matrix-degrading enzymes for the treatment and prevention of S. aureus-as
  • 批准号:
    8608900
  • 项目类别:
  • 资助金额:
    $12.99万
  • 财政年份:
    2012
  • 负责人:
    JEFFREY B KAPLAN
  • 依托单位:
海外基金